Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety
In this preliminary report initial dose reduction of SG negatively impacted PFS and OS without reducing toxicity, highlighting the need for further studies and dosing policy adjustments.
Authors
- Renata Pacholczak‐Madej (ORCID: https://orcid.org/0000-0002-6535-4841)
- Zuzana Bielčiková (ORCID: https://orcid.org/0000-0001-8434-9848)
- Michał Jarząb (ORCID: https://orcid.org/0000-0002-2642-9724)
- Małgorzata Pieniążek (ORCID: https://orcid.org/0000-0001-5864-0877)
- Aleksandra Łacko
- Marcin Kubeczko (ORCID: https://orcid.org/0000-0003-1877-5691)
- Manuela Las‐Jankowska (ORCID: https://orcid.org/0000-0002-3970-0368)
- Anna Polakiewicz-Gilowska (ORCID: https://orcid.org/0000-0002-2175-7067)
- Mirosława Püsküllüoğlu (ORCID: https://orcid.org/0000-0002-2647-9625)
Institutions
- Jagiellonian University (PL)
- Charles University (CZ)
- Medical University of Warsaw (PL)
- Nicolaus Copernicus University (PL)
- University of Bydgoszcz (PL)
- Greater Poland Cancer Center (PL)
- National Institute of Oncology (HU)
- Medical University of Lodz (PL)
- Lublin Oncology Center (PL)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- General University Hospital in Prague (CZ)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1007/s00280-025-04823-3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00